

The Niosome As A Medication Delivery System Is A Revolutionary Concept

Sai Maheswari. K¹, Ramya Bala Prabha. G², Rama Rao. T³

¹Dept of Pharm D

²Assistant Professor, Dept of Pharm D

³Professor and Principal

^{1, 2, 3} CMR College of Pharmacy, Kandlakoya, Hyderabad.

Abstract- This is an overview of niosome as a drug carrier, which enhances drug availability and can be utilized to target medications to specific body sites. Niosome have the potential to minimize pharmacological adverse effects and improve treatment efficacy in variety of disorders. The initial metabolism through liver and the low therapeutic efficacy of target site are endemic for new drug molecule. Both hydrophilic and hydrophobic medicines can be entrapped by niosome. The system has optimistic prospects in the pharmaceutical sector, mainly due to the increased availability of innovative initiatives. Niosomal carriers are good for antioxidants, anticancer, anti-inflammatory, antimicrobial, antibacterial compounds and this review compiles a comprehensive collection of recent studies in fascinating topic, with a focus on enhancing niosome potential.

Keywords- Niosome, Surfactant, Method of Preparation, Applications.

I. INTRODUCTION

When Paul Ehrlich predicted a medication delivery method that would target diseased cells directly in 1909, he used in a new age of target drug research. Immunoglobulin, serum protein, microspheres, liposomes, synthetic polymers, Niosome, and the other drug carriers are examples of drug carriers that are used to transport drugs to target organ system.¹

This article gives a high-level summary of Niosome concerns, including their chemical composition, structural benefits and applications.

Niosome are vesicle nano carriers that have attracted a lot of interest as a potential medicine delivery mechanism due to their unique benefits. They have a lamellar structure with amphiphilic molecules in the Centre and an aqueous compartment on the outside. Niosome unusual structure as vesicular system allows them to be encapsulated in the inner

water core and lipophilic substances partitioned into the lipophilic domain of bilayers.²

Because of its low toxicity, and good intrinsic skin permeation encapsulating the medicine in a niosome helps protect the molecule against acidic and enzymatic destruction after injection. The novel medication delivery technology has drawbacks such as a high cost that makes production difficult and a challenge with dose adjustment. This difficulty can be solved by adopting a vehicle drug delivery method such as Niosome, which can prolong the drug's presence in systemic circulation, boost skin permeation and lower toxicity.³

Advantages and disadvantages :

Niosome have several advantages as of nanocarriers:

1. Niosome increase drug bioavailability by shielding/protecting the drug from acidic and enzymatic degradation in the GI tract. As a result, drug bioavailability is improved.
2. Niosome have hydrophilic, lipophilic and amphiphilic structures, which allows us to incorporate a wide range of drug moieties and use them for a wide range of drugs.
3. Niosome are naturally osmotically active and stable.
4. The use of Niosome can also increase skin permeation.
5. Slowing the clearance of drug molecules from the circulation improves their therapeutic efficiency.
6. Surfactant can be easily handled and stored in any condition


At the same, Niosome have some disadvantages,

1. Drug molecules clump together.
2. Instability of the physical body.
3. It's possible that a medication that's been entrapped will leak.
4. The shelf life of an encapsulated medication can be shortened by hydrolysis.

5. It takes a long time.⁴

STRUCTURE OF NIOSOME:

A typical Niosome vesicle-forming amphiphilic surfactant, such as Span-60, which is normally stabilized by the addition of cholesterol, and a little quantity of anionic surfactant, such as diacetyl phosphate, which also aids in vesicle stabilization. The hydrophilic ends of a nonionic surfactant are exposed on the outside and interior of the vesicle in Niosome, while the hydrophobic chains express each other within the bilayer. Monomer units aggregate into vesicles, which form closed bilayer structures. This is due to the high interfacial tension between water and the hydrophobic tail. Some contribution energy, such as mechanical(stirring or sonicates) or heat, is required to achieve these structures.⁵



FACTORS GOVERNING NIOSOME FORMATION:

Surfactant and lipid level:

To make Niosomal scatterings the surfactant/lipid level is for the most part kept 10-30mM. Assuming the surfactant, water proportion is changed during the hydration step might influence the microstructure of the framework and its properties. On the off chance that we expanding the lipid level the aggregate sum of medication likewise increments.

Nature of the embodied medication:

The epitomized drug connects with surfactant head gatherings and fosters the charge that makes shared between surfactant bilayers and subsequently vesicle size increments and furthermore cause the total of vesicle, which is forestalled by utilizing electrostatic stabilizers like dicetyl phosphate in 5(6)-carboxyfluorescein.

Structure of surfactant:

Calculation of vesicle to be framed can be predicated based on basic boundaries of surfactants. Critical pressing boundaries can be characterized utilizing following condition.

$CPP = \frac{V}{lc} \cdot a_0$ where v = hydrophobic gathering volume, lc = the basic hydrophobic gathering length, a_0 = the area of hydrophilic

Temperature of hydration:

Hydration temperature impacts the shape and size of the Niosome, temperature change of Niosomal framework influences get together of surfactants into vesicles by which initiates vesicle shape change. In a perfect world the hydration temperature for Niosome development ought to be over the gel.⁶

COMPONENTS OF NIOSOMES:

The following are the two main ingredients required to make Niosome:

1. Cholesterol is a type of fat.
2. Nonionic surfactant

Cholesterol is a steroid derivative that is utilized to give Niosome preparations stiffness and appropriate shape and conformation. Nonionic surfactants are the second type of nonionic surfactant. For the manufacture of Niosome, the following non-ionic surfactants are commonly utilized E.G. Lengths(span 60,40,20,85,80). Nonionic surfactants have a hydrophilic and hydrophobic head.⁷

NIOSOME CHARACTERIZATION:

For clinical uses, Niosome characterization is critical. The stability of Niosome is directly influenced by characterization criteria, which also have a substantial impact on their in vivo performance. As a result, these characteristics must be assessed, including shape, size, polydispersity index(PI), number of lamellae, zeta potential, encapsulation efficiency, and stability.⁸

METHOD OF PREPARATION:

When compared to the ether injection approach, the hand shaking method produces vesicles with a larger diameter (0.35-13nm)(50-1,000nm). The Reverse Phase Evaporation (REV) method can be used to make small Niosome. The microfluidisation process produces more homogeneous vesicles with smaller sizes.

Osmotic stress resistance when a hypertonic salt solution is added to a Niosome suspension, the diameter of the Niosome shrinks. Slow release with small enlargement of vesicles occurs in hypotonic salt solution, perhaps due to inhibition of eluting fluid from vesicles, followed by rapid release, possibly due to mechanical loosening of vesicle structure under osmotic stress.⁹

APPLICATIONS:

Niosome as a haemoglobin transporter:

because Niosomal suspension has a visible spectrum that is superimposed over that of free haemoglobin, it can be employed as a haemoglobin carrier. Vesicles are oxygen permeable, and the haemoglobin dissociation curve can be altered in the same way as non-encapsulated haemoglobin. Niosome as medication carrier:

Iobitridol, a symptomatic operator used in X-ray imaging, has also been transported using Niosome as transporters. Topical Niosome can act as a solubilization grid, a neighborhood station for the continued arrival of dermally dynamic mixes, entry enhancers, or a rate-restricting layer blockage for the fine-tuning of foundational medicine absorption.

Delivery of ophthalmic drugs:

Due to tear production and the impermeability of the eye, it is difficult to attain optimal bioavailability of drugs in ophthalmic solution, suspension, and ointment.

Niosome are used to administer medications transdermally. When a medicine is absorbed into the skin via the transdermal method of administration, drug penetration via the skin is improved by Niosome.

Neoplasia:

Doxorubicin is an anthracyclenic antibiotic that shows broad-spectrum ant-tumor action, with dose-dependent effects, anti-irreversible cardiotoxic effect, is drug lengthened people's lives. When administered, it reduced the rate of sarcoma proliferation. Via Niosomal administration into S-180 tumor-bearing mice.

Use in immunological research:

Because of their immunological selectivity, low risk, and other factors, they are becoming increasingly popular.

Significant solidity: Niosome are being used to examine the concept.

Antigen:

It can cause an insusceptible reaction. Nonionic surfactant is a type of nonionic surfactant that is vesicle has a parenteral arrangement that contains a variety of antigen and peptide.¹⁰

RECENT STUDIES:

Over the past many years Niosome have been effectively utilized as medication transporters to overcome some major biopharmaceutical issues, for example, insolubility adverse effects, and decreased chemical stability of medication particles.

II. CONCLUSION

Niosome have been demonstrated to be promoting controlled delivery systems for both hydrophilic and lipophilic drugs. The potential of Niosome can be enhanced by using novel preparation, loading and modification methods. Researchers should be alert in need for appropriate selection of suitable surfactant for preparation of Niosome.

REFERENCES

- [1] Bhardwaj.P, Tripathi. P, Gupta. R, Pandey. S, Niosome: A Review on Niosomal Research in the Last Decade. 2020; 56.
- [2] Muzzalupu. R, Taran. C, Niosomal Drug Delivery for Transdermal Targeting Recent advances of Research and Report, Transdermal Drug Delivery. 2015; 23-33.
- [3] Harshil. M, Patel BO, Review on Niosome- A Novel Approach for Drug Targeting. International Journal of Advances in Pharmaceutics,2019;08(01);2320-4931.
- [4] Sahu. K, Niosome as Novel Drug Delivery System: A Review Article; Pharmatutor;313001.
- [5] Gharbavi M, Amani J, Manjili KH. Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier. Advances in Pharmacological and Pharmaceutical sciences; 2018;6847971.
- [6] Lohumi et al. A Novel Drug Delivery System: Niosome Review; Journal of Drug Delivery and Therapeutics; 2012,2(5);129-135.
- [7] 7.Sharma. D, Ali AAE, Aate JR; Niosome as Novel Drug Delivery System: Review Article: Pharma tutor ; 2018; 6(3):58-65.

- [8] Selegi M, Walter GJ, Scheper T. Niosome as Nanoparticulate Drug Carriers Fundamentals and Recent Applications; Journal of Nanomaterials, 2016; 7372306.
- [9] Kazi MK, Mandal SA, Biswas N, Guha A, Chatterjee S, J Adv Pharm Techno/Res 2010;1(4);374-380.
- [10] Sanklecha VM, Pande VV, Pawas SS, Pangar OB; Review on Niosome; Austin Pharmacol pharm; 2018;3(2);1016.